Objective: This study aimed to discuss the demographic, biochemical data, treatment and outcome status of patienedts we follow with acute pancreatitis in the light of current literature data.Material and Methods: Two hundred and sixty patients were included in the study. Age, sex, additional disease information, etiological cause, endoscopic retrograde cholangiopancreatography (ERCP) results, patients' service, intensive care and total hospitalization times, Ranson scores and outcomes were recorded from the file data. Hemogram and biochemical parameter levels of the patients were recorded. All analyzes were done using SPSS 22.0 statistical software package. Continuous variables in group data were indicated with mean ± standard deviation. Categorical variables were stated with numbers and percentages. While Student's t test was used in the analysis of continuous variables with normal distribution, Mann-Whitney U test was used for independent intergroup comparison of continuous or ordinal dependent variables of non-normally distributed or different groups. According to the etiology, hospitalization times and Ranson scores were compared using the Kruskal Wallis test. Whether there is a relationship between the countable parameters or not was evaluated by the "Pearson's and Spearman's" correlation analysis. Statistical significance was accepted if p< 0.05.Results: Mean age of the patients was 62.99 ± 17.8. It was determined that the group with the longest intensive care unit hospitalization period was in the group connected to gallstones. The longest hospitalization period was in the group of patients with alcohol-induced acute pancreatitis. Ward, intensive care and total hospital stay were found to be significantly higher in the ERCP group.
Conclusion:Acute pancreatitis is a disease that has a regionally different etiology, and differences in preferred scoring system and treatment modality. Being one of the most common gastrointestinal diseases in the world and increasing in frequency necessitate the evaluation of this disease with new data and different perspectives.